Business Context and Reporting Period
This Form 8-K Current Report was filed by BioXcel Therapeutics, Inc. on August 11, 2025. The filing primarily addresses compliance with a specific financing covenant under the company's credit agreement and announces management participation in an upcoming investor conference.
Key Financial Metrics and Capital Activities
The filing details a series of capital raising activities undertaken to satisfy the "Oaktree Financing Covenant," which required the company to raise specific amounts of net cash proceeds by defined deadlines.
- November 2024 Financing: Raised approximately $6.2 million in net proceeds via a public offering of common stock, warrants, and pre-funded warrants.
- March 2025 Financing: Raised approximately $13.0 million in net proceeds via a registered direct offering of common stock, warrants, and pre-funded warrants.
- ATM Program (At-The-Market): Initiated in April 2025 with an initial capacity of $8.135 million, expanded in August 2025 by an additional $3.5 million. As of August 8, 2025, the company sold 5,774,018 shares for approximately $11.2 million in net proceeds.
- Total Capital Raised: Aggregate net proceeds from these financings totaled approximately $30.4 million as of August 8, 2025.
- Outstanding Shares: Following these transactions and the exercise of pre-funded warrants, the company had 13,709,124 shares of Common Stock outstanding as of August 8, 2025.
The filing does not provide specific data on revenue, operating profit, cash flow from operations, or debt balances outside of the covenant context.
Material Changes and Covenant Compliance
The primary material change reported is the successful satisfaction of the Oaktree Financing Covenant. The covenant required three milestones:
- Raise 1: At least $7.0 million in gross proceeds by November 27, 2024.
- Raise 2: At least $18.0 million in net proceeds by March 15, 2025.
- Final Milestone: At least $29.0 million in net proceeds by the earlier of August 15, 2025, or 30 days after the SERENITY At-Home Phase 3 trial data readout.
The company confirmed that the aggregate $30.4 million raised satisfies the final $29.0 million requirement, thereby maintaining compliance with its credit agreement.
Outlook, Management Commentary, and Risks
Conference Participation: CEO Vimal Mehta, Ph.D., is scheduled to participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025, at 12 p.m. ET.
Risks and Contingencies: The filing highlights the critical nature of the financing covenant tied to the company's credit facility with Oaktree Fund Administration LLC. Failure to meet these capital raise milestones would have constituted a default under the credit agreement. The company has now mitigated this specific risk by exceeding the required threshold.
Investor Verification Checklist
- Verify the exact date of the SERENITY At-Home Phase 3 trial data readout to confirm the specific deadline trigger for the final financing milestone.
- Review the attached Press Release (Exhibit 99.1) for details on the upcoming conference presentation.
- Confirm the remaining capacity under the ATM Program following the August 6, 2025, expansion.
- Check subsequent filings for any updates on the company's cash position and burn rate post-financing.